.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

FDA's $6.4 Billion Plan for Quick Reviews Moves to Senate

May 21, 2012

Mylan Inc.

(MYL)

Pfizer Inc. (PFE)

A $6.4 billion effort to speed U.S. reviews of new drugs and medical devices is a step closer to law as the agreements , and other companies struck with regulators wind through Congress.

The Senate is set to begin voting as soon as today on more than $2 billion in new fees that drug and device companies will pay regulators through 2017 to review products for safety and efficacy. The figure includes $1.56 billion from generic-drug companies such as Canonsburg, Pennsylvania-based Mylan, which had been exempt from such fees.

Read the full story: http://hcp.lv/MB3OCO

Source: Bloomberg